Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LIRAGLUTIDE vs EXENATIDE SYNTHETIC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Glucagon-like peptide-1 (GLP-1) receptor agonist; increases insulin secretion, decreases glucagon secretion, slows gastric emptying, and promotes satiety.
Exenatide synthetic is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics the incretin hormone GLP-1, enhancing glucose-dependent insulin secretion from pancreatic beta cells, suppressing glucagon secretion, slowing gastric emptying, and promoting satiety.
Type 2 diabetes mellitus,Adjunct to diet and exercise for glycemic control,Chronic weight management (BMI ≥30 kg/m² or ≥27 kg/m² with at least one weight-related comorbidity)
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus,Reduction of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease (off-label use based on EXSCEL trial)
Liraglutide is administered subcutaneously once daily. For type 2 diabetes, start at 0.6 mg daily for one week, then increase to 1.2 mg daily; may further increase to 1.8 mg daily if needed. For weight management (with BMI ≥30 or ≥27 with comorbidities), start at 0.6 mg daily for one week, then escalate weekly by 0.6 mg to a target dose of 3.0 mg daily.
Subcutaneously 5 mcg twice daily within 60 minutes before morning and evening meals; may increase to 10 mcg twice daily after 1 month.
The terminal elimination half-life of liraglutide after subcutaneous administration is approximately 13 hours, supporting once-daily dosing. The prolonged half-life is due to albumin binding and reduced renal clearance.
Terminal elimination half-life is 2.4 hours for subcutaneous administration, supporting twice-daily dosing.
Degraded by endogenous peptidases (DPP-4 and neutral endopeptidases); no CYP450 involvement; metabolites are inactive.
Exenatide is primarily degraded by proteolytic degradation (neutral endopeptidase) and renal filtration, with minimal hepatic metabolism.
Liraglutide is primarily eliminated via degradation into smaller peptides and amino acids, with no significant renal or biliary excretion of the intact drug. Approximately 6% of the dose is excreted unchanged in urine, and less than 5% is excreted in feces as intact liraglutide.
Primarily renal via glomerular filtration and proteolytic degradation; approximately 30% of the dose is excreted unchanged in urine, with the remainder as metabolites in urine and feces.
Liraglutide is >98% bound to plasma proteins, primarily albumin. This high binding contributes to its long half-life.
Approximately 25% bound to plasma proteins, primarily albumin.
The volume of distribution after subcutaneous administration is approximately 0.07 L/kg, indicating limited extravascular distribution and primarily remaining in the circulation.
Volume of distribution is 0.2 L/kg, indicating limited extravascular distribution.
Subcutaneous: Absolute bioavailability is approximately 55% (range 46-64%). Oral bioavailability is negligible (<1%) due to enzymatic degradation in the gastrointestinal tract.
Subcutaneous: absolute bioavailability is approximately 65%.
No dose adjustment required for mild renal impairment (e GFR ≥60 m L/min/1.73 m²). For moderate impairment (e GFR 30-59), use with caution; limited data. Contraindicated in end-stage renal disease (e GFR <15). No experience in severe impairment (e GFR 15-29); use not recommended.
Cr Cl 30-50 m L/min: no adjustment; Cr Cl <30 m L/min: not recommended; ESRD on dialysis: contraindicated.
No dose adjustment needed for mild hepatic impairment (Child-Pugh class A). Not recommended for moderate to severe hepatic impairment (Child-Pugh class B or C) due to lack of data.
No specific adjustment for mild to moderate hepatic impairment; not studied in severe impairment (Child-Pugh C).
Not approved for pediatric patients under 18 years of age for either type 2 diabetes or weight management.
Not approved for use in pediatric patients; safety and efficacy not established.
No dose adjustment based solely on age. Caution in patients ≥75 years due to limited therapeutic experience; monitor renal function and gastrointestinal tolerability.
No specific dose adjustment; use caution due to increased risk of renal impairment and hypoglycemia; monitor renal function.
Risk of thyroid C-cell tumors; contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
No black box warning.
Acute pancreatitis,Risk of hypoglycemia with insulin secretagogues,Acute kidney injury,Hypersensitivity reactions (e.g., anaphylaxis, angioedema),Heart rate increase,Cholelithiasis and cholecystitis
Risk of acute pancreatitis; discontinue if suspected,Risk of hypoglycemia when used with insulin secretagogues or insulin,Renal impairment: increased risk of gastrointestinal adverse effects and acute renal failure; avoid in end-stage renal disease,Severe gastrointestinal disease: may exacerbate gastroparesis,Thyroid C-cell tumors: observed in rodent studies; monitor for serum calcitonin or thyroid masses,Immunogenicity: may develop anti-exenatide antibodies leading to loss of efficacy or injection site reactions
Personal or family history of medullary thyroid carcinoma,Multiple Endocrine Neoplasia syndrome type 2,Hypersensitivity to liraglutide or any product components
History of hypersensitivity to exenatide or any product components,Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2),End-stage renal disease (e GFR <15 m L/min/1.73 m²) or severe renal impairment (e GFR 15-29 m L/min/1.73 m²) if on dialysis,Severe gastrointestinal disease (e.g., gastroparesis)
No specific food-drug interactions. Because liraglutide delays gastric emptying, high-fat meals may worsen nausea; advise low-fat meals during titration. Avoid excessive alcohol consumption as it may increase risk of pancreatitis.
Exenatide slows gastric emptying, which may reduce the rate and extent of absorption of oral medications. Take exenatide at least 1 hour before meals; for oral medications requiring rapid absorption (e.g., antibiotics, oral contraceptives), take them 1 hour before or 4 hours after exenatide. No specific food restrictions, but high-fat meals may increase nausea.
Liraglutide is contraindicated in pregnancy. Based on animal studies, it may cause fetal harm. First trimester: avoid use due to potential for malformations. Second and third trimesters: not recommended due to risks of fetal growth restriction and other adverse outcomes.
Pregnancy Category C. In animal studies, exenatide caused reduced fetal growth, decreased ossification, and increased incidence of skeletal abnormalities at doses 5-13 times human exposure. No adequate human studies. Risk cannot be ruled out; use only if potential benefit justifies potential risk to fetus.
Liraglutide is excreted in rat milk at a 3-11% ratio relative to maternal plasma; human data unavailable. Not recommended during breastfeeding due to unknown risks to the infant. M/P ratio not determined in humans.
It is unknown whether exenatide is excreted in human breast milk. Due to potential for adverse reactions in nursing infants, caution should be exercised. M/P ratio not available. Consider developmental and health benefits of breastfeeding along with mother's clinical need for exenatide.
No dose adjustments established as liraglutide is contraindicated in pregnancy. Physiological changes in pregnancy affect pharmacokinetics, but use is not recommended.
No specific pharmacokinetic studies in pregnancy. Pregnancy-related weight gain, volume expansion, and renal changes may alter exenatide pharmacokinetics. Clinical trials did not establish a dose adjustment protocol; use the lowest effective dose titrated based on glycemic control. Discontinue prior to expected delivery (e.g., 48 hours) due to risk of delayed gastric emptying during labor.
Liraglutide is a GLP-1 receptor agonist with a 13-hour half-life, allowing once-daily dosing. Titrate weekly from 0.6 mg to 1.8 mg for diabetes or up to 3.0 mg for weight management. Monitor for pancreatitis; discontinue if suspected. Contraindicated in patients with personal/family history of medullary thyroid carcinoma or MEN2. Use with caution in renal impairment (e GFR <30). Risk of hypoglycemia when combined with insulin or sulfonylureas; consider dose reduction of these agents. Gastrointestinal side effects (nausea, vomiting, diarrhea) are common; gradual titration mitigates these. Can delay gastric emptying, affecting absorption of oral medications. Effective for glycemic control and weight loss; also reduces cardiovascular risk in T2DM patients with established CVD.
Exenatide is a GLP-1 receptor agonist used for T2DM. It slows gastric emptying, so administer at least 60 min before first meal of day. Avoid in severe renal impairment (Cr Cl <30 m L/min). Risk of acute pancreatitis; discontinue if suspected. Not for use in T1DM or DKA. Monitor for thyroid C-cell tumors (contraindicated if personal/family history of MTC or MEN 2).
Inject liraglutide once daily at the same time, regardless of meals, subcutaneously in abdomen, thigh, or upper arm.,Start with 0.6 mg daily for one week, then increase by 0.6 mg weekly to target dose (max 1.8 mg for diabetes, 3.0 mg for weight loss).,If a dose is missed, skip it and take the next dose at the usual time; do not double up.,Common side effects include nausea, vomiting, diarrhea, and constipation; these often improve over time. Eat smaller, low-fat meals to reduce nausea.,Seek medical help immediately if you experience severe abdominal pain (possible pancreatitis) or a lump in the neck, hoarseness, or trouble swallowing (possible thyroid tumor).,Do not use if you or your family have had medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.,Monitor blood glucose regularly if using insulin or sulfonylureas; adjust doses as instructed to avoid low blood sugar.,This medication can cause weight loss; inform your doctor if unintended weight loss occurs.,Store in refrigerator; after first use, can be stored at room temperature for up to 30 days.
Inject subcutaneously in abdomen, thigh, or upper arm, within 60 minutes before morning and evening meals (or before the two main meals of the day, at least 6 hours apart).,Do not administer after a meal; skip dose if a meal is skipped.,Store unused pens in refrigerator (36°F to 46°F). In-use pen can be kept at room temperature up to 86°F for up to 30 days.,Common side effects include nausea, vomiting, diarrhea, and headache; these often decrease over time.,Seek medical attention for severe abdominal pain (possible pancreatitis), rash or hives, difficulty breathing, or swelling of face/ lips (angioedema).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LIRAGLUTIDE vs EXENATIDE SYNTHETIC, answered by our medical review team.
LIRAGLUTIDE is a GLP-1 Receptor Agonist that works by Glucagon-like peptide-1 (GLP-1) receptor agonist; increases insulin secretion, decreases glucagon secretion, slows gastric emptying, and promotes satiety.. EXENATIDE SYNTHETIC is a GLP-1 Receptor Agonist that works by Exenatide synthetic is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics the incretin hormone GLP-1, enhancing glucose-dependent insulin secretion from pancreatic beta cells, suppressing glucagon secretion, slowing gastric emptying, and promoting satiety.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LIRAGLUTIDE and EXENATIDE SYNTHETIC depend on the specific clinical indication. These are both GLP-1 Receptor Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LIRAGLUTIDE is: Liraglutide is administered subcutaneously once daily. For type 2 diabetes, start at 0.6 mg daily for one week, then increase to 1.2 mg daily; may further increase to 1.8 mg daily if needed. For weight management (with BMI ≥30 or ≥27 with comorbidities), start at 0.6 mg daily for one week, then escalate weekly by 0.6 mg to a target dose of 3.0 mg daily.. The standard adult dose of EXENATIDE SYNTHETIC is: Subcutaneously 5 mcg twice daily within 60 minutes before morning and evening meals; may increase to 10 mcg twice daily after 1 month.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LIRAGLUTIDE and EXENATIDE SYNTHETIC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LIRAGLUTIDE is classified as Category C. Liraglutide is contraindicated in pregnancy. Based on animal studies, it may cause fetal harm. First trimester: avoid use due to potential for malformations. Second and third trime. EXENATIDE SYNTHETIC is classified as Category A/B. Pregnancy Category C. In animal studies, exenatide caused reduced fetal growth, decreased ossification, and increased incidence of skeletal abnormalities at doses 5-13 times human . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.